Results to date suggest that WM130 suppresses proliferation and self-renewal capability in both HCC and doxorubicin-resistant hepatoma cells by decreasing phosphorylation of GSK3β and subsequent degradation of β-catenin through downregulation of the CSC biomarker, EpCAM, and other stemness-related genes. This evidence concerns the gene GSK3B and hepatocellular carcinoma.